CD8A and neoplasm: In view of the anti-tumor activity of anti-N1, its ability to stimulate an inflamed TME with increased cytotoxic CD8+ T cells, and its safety, we sought to determine whether anti-N1 could boost the anti-tumor effects of anti-PD-1.